Druggio Logo

Druggio

Hemophilia

Hemophilia A and B are X-linked recessive disorders which are the most common hereditary hemorrhagic disorders caused by a deficiency or dysfunction of blood coagulation factor VIII (FVIII) and factor IX (FIX), respectively. Von Willebrand disease is caused by quantitative and/or qualitative defects of von Willebrand factor and inherited in both autosomal dominant and recessive manner.

Drugs that treat Hemophilia

Nuwiq

Approval date

2021/1/22

Treats

Esperoct

Made by

Novo Nordisk

Approval date

2019/9/20

Treats

Jivi

Made by

Bayer

Approval date

2018/9/21

Treats

Refixia

Made by

Novo Nordisk

Approval date

2018/7/2

Treats

Hemlibra

Approval date

2018/3/23

Treats

Afstyla

Made by

CSL Behring

Approval date

2017/9/27

Treats

Idelvion

Made by

CSL Behring

Approval date

2016/9/28

Treats

Kovaltry

Made by

Bayer

Approval date

2016/3/28

Treats

Adynovate

Made by

Takeda

Approval date

2016/3/28

Treats

Eloctate

Made by

Sanofi

Approval date

2014/12/26

Treats

Rixubis

Made by

Baxter

Approval date

2014/12/26

Treats

Alprolix

Made by

Sanofi

Approval date

2014/7/4

Treats

NovoEight

Made by

Novo Nordisk

Approval date

2014/1/17

Treats

BeneFIX

Made by

Pfizer

Approval date

2009/10/16

Treats

Advate

Made by

Baxter

Approval date

2006/10/20

Treats

NovoSeven

Made by

Novo Nordisk

Approval date

2000/3/10